ibrutinib
abbvie,janssen
['biotec', 'abbvie']
txbn news #asco22: imbruvica keeps aggressive blood cancer at bay for 6+ years, but misses the mark in overall survival: johnson &amp; johnson and abbvie popped the cork on some preliminary data showing imbruvica, ... #biotech #news 
#LifeScience #news, #jobs and #events from the #Texas region, including #Dallas #Austin #Houston. Part of @BiotechNetworks, connecting #biotech since 2008.